Go 6983
别名: GOE 6983, Gö 6983
Go 6983 (GOE 6983, Gö 6983)是一种pan-PKC抑制剂，作用于PKCα， PKCβ， PKCγ和PKCδ，IC50分别为7 nM， 7 nM， 6 nM和10 nM，对PKCζ作用稍弱，抑制PKCμ活性。
Go 6983 Chemical Structure
CAS: 133053-19-7
客户使用Selleck的Go 6983发表文献84篇
产品质控
Go 6983相关产品
相关信号通路图
PKC抑制剂选择性比较
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| KM20 | Function assay | 2 μM | 8 h | attenuated PMA-induced FLIP mRNA expression | 16052516 |
| HT29 | Function assay | 2 μM | 8 h | attenuated PMA-induced FLIP mRNA expression | 16052516 |
| HCT116 | Function assay | 2 μM | 8 h | attenuated PMA-induced FLIP mRNA expression | 16052516 |
| PC-3 | Function assay | 1 μM | 2 h | Gö6983 abrogates the TPA-induced RGFR transactivation response | 15897236 |
| KM12C | Function assay | 2 μM | 8 h | attenuated PMA-induced FLIP mRNA expression | 16052516 |
| Caco-2 | Function assay | 2 μM | 8 h | completely attenuated PMA-induced FLIP mRNA expression | 16052516 |
| A549 | Function assay | 10 μM | 1 h | markedly inhibited ATPγS-stimulated NADPH oxidase activity and H2O2 and/or ROS generation | 23326583 |
| HeLa | Function assay | 2 μM | 48 h | suppressed the effect of PMA on apicularen A-induced cytotoxicity | 24447339 |
| PC12 | Function assay | 0.5 μM | GO6983 blocked the effect of PMA on the activation of Akt and MAPK induced by IGF-1 | 10788447 | |
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | ||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | ||
| HEK293 | Function assay | Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in human HEK293 cells transfected with rabbit L-type calcium channel subunits, IC50 = 20 μM. | ChEMBL | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Go 6983 (GOE 6983, Gö 6983)是一种pan-PKC抑制剂，作用于PKCα， PKCβ， PKCγ和PKCδ，IC50分别为7 nM， 7 nM， 6 nM和10 nM，对PKCζ作用稍弱，抑制PKCμ活性。 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | Gö 6983(300 μM)作用于转染PKCμ的NIH3T3细胞，抑制PKCμ自磷酸化，降低20%。[1] 心脏再灌注PMNs和Gö 6983 (100 nM)，左心室发展压（LVDP）和LVDP率分别恢复到基准值的89％和74％，显著高于PMNs单独处理。与心脏缺血再灌注（I/R）+ PMN 相比，Gö 6983 (100 nM)显著降低PMNs黏附到内皮细胞和浸润到心肌，且显著抑制超氧化物从PMNs中释放，抑制达90％。在PMNs存在时，Gö 6983降低I/R后心肌收缩功能障碍，这可能与降低超氧化物的产生部分相关。[2] Gö 6983显著抑制抗原诱导的超氧化物从以前对树花粉过敏的患者白细胞中释放。Gö 6983作用于人类血管组织，抑制细胞内的Ca(2+)累积，说明其血管舒张特性机制。[3] Go-6983(1 μM)与Ro-31-8425(390 nM)联用作用于PGSMCs，轻微抑制Angiotensin II诱导的PLD2活性。[4] Gö 6983 是亚型特异性的PKC抑制剂，靶向作用于ATP 结合位点。Gö 6983抑制ΔPfPKB活性，IC50为1 μM。Gö 6983(5 μM)处理过的细胞中，与对照培养物相比，下一细胞周期环数显著减少。Gö 6983 (5 μM) 处理P. falciparum培养物，使新环形成减少近60％。[5] |
|||
|---|---|---|---|---|
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | PKCη / PKCα / PKCδ / PKCε |
|
22892130 | |
| 体内研究(In Vivo) | ||
| 体内研究活性 |
在小鼠肺B16BL6肿瘤模型中，Go6983 (22.0 μg/mouse, i.v.)强烈抑制51.2 %的肿瘤转移。[6] |
|
|---|---|---|
化学信息&溶解度
| 分子量 | 442.51 | 分子式 | C26H26N4O3 |
| CAS号 | 133053-19-7 | SDF | Download Go 6983 SDF |
| Smiles | CN(C)CCCN1C=C(C2=C1C=CC(=C2)OC)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54 | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 89 mg/mL ( (201.12 mM)； DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
